Compare Stocks: ANL, VKTX, PBLS, and XENE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$11.76 -17.3%	$14.57	$0.88 ▼ $17.25	$757.34M	1.05	367,892 shs	957,690 shs
PBLS Parabilis Medicines	$26.85 -7.3%	$35.83	$24.51 ▼ $42.49	$3.32B	N/A	754,933 shs	1.19 million shs
VKTX Viking Therapeutics	$26.65 -6.0%	$32.77	$25.77 ▼ $43.15	$3.36B	0.66	3.20 million shs	5.70 million shs
XENE Xenon Pharmaceuticals	$34.42 -3.9%	$52.45	$34.38 ▼ $72.66	$3.33B	0.6	1.40 million shs	1.11 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	-8.96%	-5.45%	-6.51%	+54.57%	+761.82%
PBLS Parabilis Medicines	+5.35%	-1.96%	-21.50%	-7.06%	+2,894,999,900.00%
VKTX Viking Therapeutics	-0.60%	-3.21%	-11.38%	-25.36%	-15.55%
XENE Xenon Pharmaceuticals	-1.73%	-4.68%	-38.94%	-46.79%	-9.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$11.76 -17.3%	$14.57	$0.88 ▼ $17.25	$757.34M	1.05	367,892 shs	957,690 shs
PBLS Parabilis Medicines	$26.85 -7.3%	$35.83	$24.51 ▼ $42.49	$3.32B	N/A	754,933 shs	1.19 million shs
VKTX Viking Therapeutics	$26.65 -6.0%	$32.77	$25.77 ▼ $43.15	$3.36B	0.66	3.20 million shs	5.70 million shs
XENE Xenon Pharmaceuticals	$34.42 -3.9%	$52.45	$34.38 ▼ $72.66	$3.33B	0.6	1.40 million shs	1.11 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	-8.96%	-5.45%	-6.51%	+54.57%	+761.82%
PBLS Parabilis Medicines	+5.35%	-1.96%	-21.50%	-7.06%	+2,894,999,900.00%
VKTX Viking Therapeutics	-0.60%	-3.21%	-11.38%	-25.36%	-15.55%
XENE Xenon Pharmaceuticals	-1.73%	-4.68%	-38.94%	-46.79%	-9.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.86	Moderate Buy	$29.50	150.85% Upside
PBLS Parabilis Medicines	2.71	Moderate Buy	$41.67	55.18% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$99.44	273.15% Upside
XENE Xenon Pharmaceuticals	2.87	Moderate Buy	$70.14	103.79% Upside

Current Analyst Ratings Breakdown

Latest ANL, VKTX, PBLS, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	ANL Adlai Nortye	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/7/2026	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$87.00 ➝ $85.00
10/6/2026	XENE Xenon Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$73.00
10/5/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/2/2026	PBLS Parabilis Medicines	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D)
10/2/2026	XENE Xenon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/28/2026	XENE Xenon Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$90.00
9/23/2026	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$83.00 ➝ $87.00
9/22/2026	VKTX Viking Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$120.00
9/22/2026	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/22/2026	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$5M	151.47	N/A	N/A	($0.21) per share	-56.00
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A
XENE Xenon Pharmaceuticals	$7.50M	443.65	N/A	N/A	$7.53 per share	4.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	-$145.89M	-$2.13	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest ANL, VKTX, PBLS, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/2/2026	Q3 2026	XENE Xenon Pharmaceuticals	-$1.13	N/A	N/A	N/A	$1.33 million	N/A
10/28/2026	Q3 2026	VKTX Viking Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	PBLS Parabilis Medicines	-$0.16	-$2.32	-$2.16	-$2.32	N/A	$0.15 million
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.04	9.55	N/A
PBLS Parabilis Medicines	N/A	17.91	17.91
VKTX Viking Therapeutics	N/A	4.72	4.72
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
PBLS Parabilis Medicines	N/A
VKTX Viking Therapeutics	76.03%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
PBLS Parabilis Medicines	N/A
VKTX Viking Therapeutics	5.30%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
PBLS Parabilis Medicines	145	123.53 million	N/A	N/A
VKTX Viking Therapeutics	65	125.99 million	119.31 million	Optionable
XENE Xenon Pharmaceuticals	364	96.67 million	93.85 million	Optionable

ANL, VKTX, PBLS, and XENE Headlines

Recent News About These Companies

Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month Low - Here's Why

October 13 at 1:39 PM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded by Wall Street Zen to "Strong Sell"

October 11 at 1:07 AM | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Cut to "Strong Sell" at Wall Street Zen

October 11 at 1:05 AM | marketbeat.com

Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now

October 9, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline

October 9, 2026 | uk.finance.yahoo.com

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

October 7, 2026 | globenewswire.com

Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year Low - Here's Why

October 6, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Given "Buy" Rating at Guggenheim

October 6, 2026 | americanbankingnews.com

Guggenheim Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

October 6, 2026 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

Xenon CFO buys 15,000 shares

October 4, 2026 | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Ian Mortimer Purchases 30,000 Shares